[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"large-ischemic-core\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:large-ischemic-core":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100644695","endovascular-therapy-for-acute-basilar-artery-occlusion-with-large-ischemic-core-100644695",false,"NCT07672795","Endovascular Therapy for Acute Basilar Artery Occlusion With Large Ischemic Core","Efficacy and Safety of Endovascular Therapy for Acute Basilar Artery Occlusion With Large Ischemic Core: A Prospective, Multicenter, Randomized Controlled Trial","Inclusion Criteria:\n\n* Clinical symptoms or imaging findings suggestive of acute posterior circulation ischemic stroke.\n* Basilar artery occlusion confirmed by CTA, MRA, or DSA.\n* Posterior circulation ASPECTS \\\u003C7 on CT, CTA source images, or MRI-DWI.\n* Age 18 to 80 years.\n* Time from symptom onset or last known well to randomization within 24 hours.\n* Written informed consent obtained from the patient or legally authorized representative.\n* Baseline NIHSS score ≥6 before randomization.\n\nExclusion Criteria:\n\n* Pre-stroke modified Rankin Scale score ≥3.\n* Pregnancy or lactation.\n* Known allergy to contrast agents or nickel-titanium alloy.\n* Current participation in another clinical trial.\n* Systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg that cannot be controlled with antihypertensive therapy.\n* Known hereditary or acquired bleeding diathesis, coagulation factor deficiency, or current oral anticoagulant use with INR \\>1.7.\n* Blood glucose \\\u003C50 mg\u002FdL or \\>400 mg\u002FdL, platelet count \\\u003C50 × 10\\^9\u002FL, or hematocrit \\\u003C25%.\n* Life expectancy less than 1 year.\n* Inability to complete 90-day follow-up.\n* Definite history of cerebral vasculitis.\n* Pre-existing neurological or psychiatric disorder that may interfere with neurological or functional assessment.\n* Intracranial hemorrhage on CT or MRI, except for cerebral microbleeds \\\u003C5 mm on MRI.\n* Vascular tortuosity, anatomical variation, or arterial dissection on CTA, MRA, or DSA that precludes endovascular treatment.\n* Intracranial tumor, except for small meningioma.","ALL","18 Years",{"count":19,"type":20},256,"ESTIMATED","INTERVENTIONAL",[23],"NA","Acute basilar artery occlusion is associated with high mortality and severe disability. Previous randomized trials have demonstrated the benefit of endovascular therapy in selected patients with basilar artery occlusion; however, patients with large ischemic core, commonly defined by low posterior circulation Alberta Stroke Program Early CT Score (pc-ASPECTS), remain underrepresented and the benefit-risk profile of endovascular therapy in this subgroup is uncertain.\n\nThis prospective, multicenter, randomized, open-label, blinded-endpoint trial will evaluate the efficacy and safety of endovascular therapy plus best medical management compared with best medical management alone in patients with acute basilar artery occlusion within 24 hours from symptom onset or last known well and pc-ASPECTS \\\u003C7. Eligible participants will be randomized in a 1:1 ratio to receive endovascular therapy plus best medical management or best medical management alone. The primary outcome is favorable functional outcome, defined as a modified Rankin Scale score of 0 to 3 at 90 days.",[26,27,28],"Acute Ischemic Stroke","Basilar Artery Occlusion","Large Ischemic Core",[30,31,32,33,34],"Basilar artery occlusion","Endovascular therapy","Mechanical thrombectomy","Posterior circulation stroke","Large ischemic core","NOT_YET_RECRUITING","2026-06-30",{"date":38,"type":39},"2026-07-02","ACTUAL",{"date":41,"type":20},"2026-08-01",{"date":43,"type":20},"2029-12-31",{"name":45,"class":46},"The First Affiliated Hospital of University of Science and Technology of China","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":4},"100610784","assessing-local-hypothermia-and-endovascular-recanalization-for-acute-stroke-with-a-large-core-infarction-100610784","NCT07232082","Assessing Local Hypothermia and Endovascular Recanalization for Acute Stroke With a Large Core Infarction","Assessing Local Hypothermia and Endovascular Recanalization for Acute Stroke With a Large Core Infarction-A Multicenter, Prospective, Open-label, Blinded-Endpoint, Randomized Controlled Trial","RESCUE-LCI","Inclusion Criteria:\n\nGeneral Inclusion Criteria：\n\n1. Age ≥18 years old.\n2. The National Institutes of Health Stroke Scale (NIHSS) score was ≥6 points before randomization.\n3. Time from symptom onset to randomization ≤24h.\n4. Patients or their guardians can understand the purpose of the trial, voluntarily participate and sign a written informed consent, and are capable of receiving clinical follow-up.\n\nSpecific Neuroimaging Inclusion Criteria\n\n1. Prior to randomization, CTA, MRA, or DSA confirmed the presence of anterior circulatory large vessel occlusion (internal carotid artery or M1segment).\n2. NCCT ASPECTS value of 3 to 5 based on findings from non-contrast CT within 24 hours after stroke onset (defined as the time the patient was last known to be well), with no limitation with respect to infarct-core volume;\n3. NCCT ASPECTS value of 0 to 2 based on findings from non-contrast CT within 24 hours after stroke onset and an infarct-core volume between 70 ml and 100 ml;\n4. NCCT ASPECTS value greater than 5 based on findings from non-contrast CT after stroke onset and an infarct-core volume of 70 to 100 ml.\n\nExclusion Criteria:\n\n1. Pre stroke mRS\\>1 score.\n2. Multivessel Occlusion\n3. Concomitant untreated intracranial aneurysms, intracranial tumors (with the exception of small meningiomas), or intracranial vascular malformations.\n4. History of intracranial hemorrhage within 6 months, including parenchymal hemorrhage, intraventricular hemorrhage, or subarachnoid hemorrhage.\n5. History of gastrointestinal hemorrhage, genitourinary bleeding, acute myocardial infarction (AMI), cranial trauma, or having undergone major surgical procedures within the past month.\n6. The presence of active bleeding, severe anemia, coagulation dysfunction, or an uncorrected bleeding tendency (platelet count \\\u003C 40,000 \u002Fμl, uncorrected INR\\>2.0).\n7. Patients with heart function of grade 1 or above, or with a clear history of acute or chronic heart dysfunction, are at greater risk of acute heart failure or fluid perfusion intolerance as determined by clinicians.\n8. Severe heart, liver, kidney disease.\n9. Known allergy to contrast media or related medications.\n10. Refractory hypertension uncontrolled by medication (defined as persistent systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg).\n11. glucose \\\u003C2.8 mmol\u002FL or \\>22.2 mmol\u002FL；\n12. Pregnancy or lactation；\n13. the expected survival time is less than 12 months.\n14. Participating in other clinical trials, in the investigational phase or in the follow-up phase.\n15. Other conditions deemed by investigators to pose significant risks or render participation unsuitable (e.g. inability to comply due to psychiatric\u002Fcognitive\u002Femotional disorders).",{"count":56,"type":20},322,[23],"A multicenter, prospective, open-label, blinded-endpoint, randomized controlled trial to assess the effectiveness and safety of catheter-based focal intracranial hypothermia combined with endovascular reperfusion therapy for acute patients with a Large Core Infarction.",[60,28],"Stroke",[62,63],"endovascular therapy","Hypothermia","2026-04-27",{"date":66,"type":39},"2026-04-28",{"date":68,"type":20},"2026-05-01",{"date":70,"type":20},"2027-04-07",{"name":72,"class":46},"First Affiliated Hospital of Wannan Medical College",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":21,"phases":83,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":102},"100599934","evt-in-acute-basilar-artery-occlusion-with-large-infarction-core-100599934","NCT07090941","EVT in Acute Basilar Artery Occlusion With Large Infarction Core","Trial of Endovascular Treatment in Acute Basilar Artery Occlusion Patients With a Large Infarct Core","BOLT","Inclusion Criteria:\n\n* 1\\. Age ≥18 years. 2. Symptoms and signs consistent with basilar artery ischemia. 3. Basilar artery or vertebral artery occlusion confirmed by computed tomography angiography (CTA), magnetic resonance angiography (MRA), digital subtraction angiography (DSA); if vertebral artery occlusion is present, it must completely obstruct blood flow to the basilar artery.\n\n  4\\. POST-NIHSS score ≥10 at randomization. 5. Time from symptom onset to randomization ≤24 hours (symptom onset defined as last known well time).\n\n  6\\. pc-ASPECTS of 3-5 on CT\u002FMRI (for patients aged \\\u003C80 years) or pc-ASPECTS of 3-7 (for patients aged ≥80 years).\n\n  7\\. Willingness of the patient or legally authorized representative to comply with protocol requirements and data collection procedures, with documented informed consent.\n\nExclusion Criteria:\n\n* 1\\. Pre-stroke modified Rankin Scale (mRS) score \\>2. 2. Factors in the target vessel that are expected to prevent completion of endovascular treatment.\n\n  3\\. Concurrent anterior and posterior circulation strokes or multivessel occlusions.\n\n  4\\. Significant mass effect with imaging or clinical signs of obstructive hydrocephalus or tonsillar herniation.\n\n  5\\. Basilar artery occlusion confirmed as chronic by prior imaging or investigator judgment.\n\n  6\\. Presence of untreated intracranial aneurysms, intracranial tumors (except small meningiomas), or intracranial vascular malformations.\n\n  7\\. Intracranial hemorrhage within the past 6 months, including parenchymal brain hemorrhage, intraventricular hemorrhage, or subarachnoid hemorrhage.\n\n  8\\. Presence of active bleeding, coagulation disorders, or uncorrectable bleeding tendencies.\n\n  9\\. Severe heart, liver, or kidney dysfunction or other severe systemic late-stage diseases.\n\n  10\\. Known allergy to iodine contrast agents or other treatment-related drugs. 11. Medically uncontrolled refractory hypertension (defined as persistent systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg) (Note: Participants can be included if their blood pressure is controllable with medication and maintained at an acceptable level).\n\n  12\\. Uncontrollable blood glucose \\\u003C2.8 mmol\u002FL or \\>22.2 mmol\u002FL. 13. Pregnancy or breastfeeding. 14. Life expectancy \\\u003C6 months. 15. Participation in other clinical studies that may affect outcome assessment. 16. Investigator's judgment that the patient is unsuitable for participation in this study or may face significant risks (e.g., due to mental illness, cognitive, or emotional disorders preventing understanding and\u002For compliance with study procedures and\u002For follow-up).",{"count":82,"type":20},348,[23],"A multicenter, prospective, open-label, blinded endpoint, randomized controlled trial designed to evaluate the efficacy and safety of best medical management (BMM) combined with endovascular treatment (EVT) versus BMM alone in acute basilar artery occlusion (BAO) patients with large infarct cores.",[27,28,86,87],"Large Core Infarct","Endovascular Treatments",[27,89,90],"Endovascular treatment","Large infarct core","RECRUITING","2025-07-21",{"date":94,"type":39},"2025-07-29",{"date":96,"type":20},"2025-08-01",{"date":98,"type":20},"2027-12-31",{"name":100,"class":101},"The First Affiliated Hospital of Hainan Medical University","OTHER_GOV",1]